Basic Information
Esbriet
Regulatory Information
EMEA/H/C/002154
Authorised
February 27, 2011
December 16, 2010
35
March 20, 2024
Company Information
Germany
Emil-Barell-Strasse 1 79639 Grenzach-Wyhlen
Roche Registration GmbH
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Esbriet is indicated in adults for the treatment of idiopathic pulmonary fibrosis.
Overview Summary
Esbriet is a medicine used to treat adults with idiopathic pulmonary fibrosis (IPF). IPF is a long-term disease in which fibrous scar tissue continuously forms in the lungs, causing persistent cough, frequent lung infections and severe shortness of breath. ‘Idiopathic’ means that the cause of the disease is unknown. Esbriet contains the active substance pirfenidone.